Atherosclerosis
Volume 212, Issue 1 , Pages 1-8 , September 2010

Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: Clinical evidence and pathophysiological mechanisms

  • Chim C. Lang

      Affiliations

    • Ninewells Hospital and Medical School, Dundee, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 1382 632180; fax: +44 1382 644972.
    • ,
  • Sandeep Gupta

      Affiliations

    • Whipps Cross and St. Bartholomews Hospitals, London, United Kingdom
    • ,
  • Paul Kalra

      Affiliations

    • Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom
    • ,
  • Bernard Keavney

      Affiliations

    • Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
    • ,
  • Ian Menown

      Affiliations

    • Craigavon Cardiac Centre, Craigavon, Northern Ireland United Kingdom
    • ,
  • Chris Morley

      Affiliations

    • Bradford Royal Infirmary, Bradford, United Kingdom
    • ,
  • Sandosh Padmanabhan

      Affiliations

    • BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

Received 20 November 2009 ,Revised 15 January 2010 ,Accepted 20 January 2010.

References 

  1. Aboyans V, Criqui MH. Can we improve cardiovascular risk prediction beyond risk equations in the physician's office?. J Clin Epidemiol. 2006;59:547–558
  2. Palatini P. Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms. Drugs. 2007;67(Suppl 2):3–13
  3. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–821
  4. Perski A, Olsson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123:609–616
  5. Huikuri HV, Jokinen V, Syvänne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19:1979–1985
  6. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477–1482
  7. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967–974
  8. Hjalmarson A, Gilpin EA, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990;65:547–553
  9. Disegni E, Goldbourt U, Reicher-Reiss H, et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. secondary prevention reinfarction israeli nifedipine trial. J Clin Epidemiol. 1995;48:1197–1205
  10. Zuanetti G, Hernández-Bernal F, Rossi A, et al. Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience. Eur Heart J. 1999;1(Suppl H):H52–H57
  11. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J. 2001;22:2085–2103
  12. Hjalmarson A. Heart rate: an independent risk factor in cardiovascular disease. Eur Heart J. 2007;9(Suppl F):F3–F7
  13. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F–49F
  14. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103:1428–1433
  15. Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the metoprolol controlled release/extended release randomised intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 2005;45:252–259
  16. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomised controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865–869
  17. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182–1187
  18. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–392
  19. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103:1721–1726
  20. Sipahi I, Tuzcu EM, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med. 2007;147:10–18
  21. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomised controlled trial. JAMA. 2004;291:1071–1080
  22. Shattock M, Camm AJ. Pure heart rate reduction: the If channels from discovery to therapeutic target. Br J Cardiol. 2006;13:27–35
  23. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–2536
  24. Ruzyllo W, Tendera M, Ford I, Fox KM. Anti-anginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393–405
  25. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674–1679
  26. Fox K, Ford I, Steg PG, Tendera M, Ferrari R BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816
  27. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomised, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337–2345
  28. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226:180–182
  29. Kaplan JR, Manuck SB, Adams MR, Weingand KW, Clarkson TB. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation. 1987;76:1364–1372
  30. Albaladejo P, Carusi A, Apartian A, et al. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res. 2003;40:320–328
  31. Custodis F, Baumhäkel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117:2377–2387
  32. Drouin A, Gendron ME, Thorin E, et al. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008;154:749–757
  33. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93:1043–1065
  34. Malik M, Camm AJ. Heart rate variability: from fact to fancies. J Am Coll Cardiol. 1993;22:566–568
  35. Bigger JT, Fleiss JL, Steinman RC, et al. Frequency-domain measures of heart period variability and mortality after myocardial infarction. Circulation. 1992;85:164–171
  36. Huikuri HV, Mäkikallio TH. Heart rate variability in ischemic heart disease. Auton Neurosci. 2001;90:95–101
  37. Rich MW, Saini JS, Kleiger RE, et al. Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography. Am J Cardiol. 1988;62:714–717
  38. Airaksinen KE, Ikäheimo MJ, Linnaluoto MK, Niemelä M, Takkunen JT. Impaired vagal heart rate control in coronary artery disease. Br Heart J. 1987;58:592–597
  39. Hayano J, Sakakibara Y, Yamada M, et al. Decreased magnitude of heart rate spectral components in coronary artery disease. Its relation to angiographic severity. Circulation. 1990;81:1217–1224
  40. Wennerblom B, Lurje L, Tygesen H, Vahisalo R, Hjalmarson A. Patients with uncomplicated coronary artery disease have reduced heart rate variability mainly affecting vagal tone. Heart. 2000;83:290–294
  41. Forslund L, Björkander I, Ericson M, et al. Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris. Heart. 2002;87:415–422
  42. Bjorkander I, Forslund L, Kahan T, et al. Differential index: a simple time-domain heart rate variability analysis with prognostic implications in stable angina pectoris. Cardiology. 2008;111:126–133
  43. Chattipakorn N, Incharoen T, Kanlop N, Chattipakorn S. Heart rate variability in myocardial infarction and heart failure. Int J Cardiol. 2007;120:289–296
  44. Lanza GA, Guido V, Galeazzi MM, et al. Prognostic role of heart rate variability in patients with a recent acute myocardial infarction. Am J Cardiol. 1998;82:1323–1328
  45. Buccelletti E, Gilardi E, Scaini E, et al. Heart rate variability and myocardial infarction: systematic literature review and metanalysis. Eur Rev Med Pharmacol Sci. 2009;13:299–307
  46. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology. 2008;33:1305–1312
  47. Sajadieh A, Nielsen OW, Rasmussen V, et al. Increased heart rate and reduced heart rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J. 2004;25:363–370
  48. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF. C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease. J Intern Med. 2006;260:377–387
  49. Rogowski O, Shapira I, Shirom A, et al. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart. 2007;93:940–944
  50. Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106:43–49
  51. Mozaffarian D, Bryson CL, Spertus JA, McDonell MB, Fihn SD. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. Am Heart J. 2003;146:1015–1022
  52. Cohn PF. Total ischemic burden: definition, mechanisms, and therapeutic implications. Am J Med. 1986;81(Suppl 4A):2–6
  53. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation. 1990;81:748–756
  54. Yeung AC, Barry J, Orav J, et al. Effects of asymptomatic ischaemia on long-term prognosis in chronic stable coronary disease. Circulation. 1991;83:1598–1604
  55. Dargie HJ, Ford I, Fox KM Total Ichaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J. 1996;17:104–112
  56. Gehi AK, Ali S, Na B, Schiller NB, Whooley MA. Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study. Arch Intern Med. 2008;168:1423–1428
  57. Tanaka N, Nozawa T, Yasumura Y, et al. Heart rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990;40:503–521
  58. Rocco MB, Barry J, Campbell S, et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation. 1987;75:395–400
  59. Deanfield JE, Maseri A, Selwyn AP, et al. Myocardial ischaemia during daily life in patients with stable angina: its relation to symptoms and heart rate changes. Lancet. 1983;2:753–758
  60. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation. 1993;88:92–100
  61. Pratt CM, McMahon RP, Goldstein S, et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). Am J Cardiol. 1996;77:1302–1309
  62. Nakagomi A, Celermajer DS, Lumley T, Freedman SB. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. Am J Cardiol. 1996;78:516–519
  63. Kloner RA, Kirshenbaum J, Lange R, Antman EM, Braunwald E. Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia. Am J Cardiol. 1985;56:40F–48F
  64. Matsuzaki M, Guth B, Tajimi T, Kemper WS, Ross J. Effect of the combination of diltiazem and atenolol on exercise-induced regional myocardial ischemia in conscious dogs. Circulation. 1985;72:233–243
  65. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284:H676–H682
  66. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther. 2004;308:236–240
  67. Feringa HH, Bax JJ, Boersma E, et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation. 2006;114(1 Suppl):I344–I349
  68. von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll Cardiol. 1996;28:20–24
  69. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation. 1990;82:1962–1972
  70. Borer JS, Fox K, Jaillon P, Lerebours G Ivabradine Investigators Group. Anti-anginal and anti-ischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomised, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–823
  71. Tardif JC, Ponikowski P, Kahan T ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomised, placebo-controlled trial. Eur Heart J. 2009;30:540–548
  72. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation. 1994;90:762–768
  73. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomised to initial strategies of medical therapy versus revascularisation. Circulation. 1997;95:2037–2043
  74. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  75. Chatzizisis YS, Coskun AU, Jonas M, et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49:2379–2393
  76. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282:2035–2042
  77. Soulis JV, Giannoglou GD, Chatzizisis YS, et al. Spatial and phasic oscillation of non-Newtonian wall shear stress in human left coronary artery bifurcation: an insight to atherogenesis. Coron Artery Dis. 2006;17:351–358
  78. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol. 1998;18:677–685
  79. Tzima E, Irani-Tehrani M, Kiosses WB, et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature. 2005;437:426–431
  80. Li YS, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech. 2005;38:1949–1971
  81. Gimbrone MA, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci. 2000;902:230–239
  82. Resnick N, Yahav H, Shay-Salit A, et al. Fluid shear stress and the vascular endothelium: for better and for worse. Prog Biophys Mol Biol. 2003;81:177–199
  83. Giannoglou GD, Chatzizisis YS, Zamboulis C, et al. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008;126:302–312
  84. Kozuma K, Costa MA, Sabaté M, et al. Relationship between tensile stress and plaque growth after balloon angioplasty treated with and without intracoronary beta-brachytherapy. Eur Heart J. 2000;21:2063–2070
  85. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol. 1996;16:1070–1073
  86. Thubrikar MJ, Robicsek F. Pressure-induced arterial wall stress and atherosclerosis. Ann Thorac Surg. 1995;59:1594–1603
  87. Palatini P, Benetos A, Grassi G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European society of hypertension consensus meeting. J Hypertens. 2006;24:603–610
  88. Bassiouny HS, Zarins CK, Kadowaki MH, Glagov S. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg. 1994;19:426–434
  89. Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens. 1996;14:897–901
  90. Mircoli L, Mangoni AA, Giannattasio C, Mancia G, Ferrari AU. Heart rate-dependent stiffening of large arteries in intact and sympathectomised rats. Hypertension. 1999;34:598–602
  91. Sa Cunha R, Pannier B, Benestos A, et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens. 1997;15:1423–1430
  92. Benetos A, Adamopoulos C, Bureau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105:1202–1207
  93. Albaladejo P, Asmar R, Safar M, Benetos A. Association between 24-hour ambulatory heart rate and arterial stiffness. J Hum Hypertens. 2000;14:137–141
  94. Giannattasio C, Vincenti A, Failla M, et al. Effects of heart rate changes on arterial distensibility in humans. Hypertension. 2003;42:253–256
  95. Wilkinson IB, MacCallum H, Flint L, et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525:263–270
  96. Wilkinson IB, Mohammad NH, Tyrrell S, et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens. 2002;15:24–30
  97. Papaioannou TG, Vlachopoulos CV, Alexopoulos NA, et al. The effect of heart rate on wave reflections may be determined by the level of aortic stiffness: clinical and technical implications. Am J Hypertens. 2008;21:334–340
  98. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation. 2006;113:1213–1225
  99. Kelly R, Daley J, Avolio A, O’Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension. 1989;14:14–21

PII: S0021-9150(10)00077-8

doi: 10.1016/j.atherosclerosis.2010.01.029

Atherosclerosis
Volume 212, Issue 1 , Pages 1-8 , September 2010

Article Tools

* Image Usage & Resolution